| Literature DB >> 31665391 |
Tammy Y N Tong1,2, Albert Koulman1,3,4,5, Julian L Griffin5,6, Nicholas J Wareham1, Nita G Forouhi1, Fumiaki Imamura1.
Abstract
BACKGROUND: Cardiometabolic benefits of the Mediterranean diet have been recognized, but underlying mechanisms are not fully understood.Entities:
Keywords: Mediterranean diet; acylcarnitines; amines; biomarkers; dietary pattern; metabolomics; molecular epidemiology; nutritional epidemiology; phospholipids; sphingolipids
Mesh:
Substances:
Year: 2020 PMID: 31665391 PMCID: PMC7315099 DOI: 10.1093/jn/nxz263
Source DB: PubMed Journal: J Nutr ISSN: 0022-3166 Impact factor: 4.798
Baseline characteristics of participants by thirds of adherence to the Mediterranean diet: the Fenland Study, 2005–2015[1]
| Adherence to the Mediterranean diet | |||
|---|---|---|---|
| Baseline characteristics | Tertile 1 (3.3–8.4 points) ( | Tertile 2 (8.4–9.7 points) ( | Tertile 3 (9.7–14.0 points) ( |
| Age, y | 48.2 ± 7.3 | 48.4 ± 7.5 | 48.3 ± 7.6 |
| Test site | |||
| Cambridge | 24.3 | 34.0 | 47.8 |
| Ely | 37.3 | 38.8 | 34.6 |
| Wisbech | 38.4 | 27.2 | 17.6 |
| Sex, women | 40.3 | 54.9 | 65.5 |
| Education level[ | |||
| Compulsory | 28.8 | 20.1 | 12.0 |
| Further | 52.4 | 46.7 | 39.1 |
| Higher | 18.8 | 33.2 | 48.9 |
| Occupation[ | |||
| Routine/tech/others | 55.4 | 40.2 | 29.1 |
| Managerial/professional | 44.6 | 59.8 | 70.9 |
| Household income | |||
| ≤£25,000 | 43.7 | 32.6 | 26.3 |
| £25,001–44,775 | 31.2 | 35.7 | 34.7 |
| ≥£44,776 | 25.1 | 31.7 | 39.0 |
| Smoking | |||
| Never | 52.6 | 54.4 | 56.0 |
| Former | 28.5 | 35.0 | 36.0 |
| Current | 18.9 | 10.6 | 8.0 |
| Energy expenditure, kJ · kg–1 · d–1 | 55.2 ± 23.4 | 52.6 ± 21.4 | 54.1 ± 21.3 |
| Medication use | 42.6 | 43.4 | 40.6 |
| Family history of diabetes | 20.2 | 22.2 | 19.0 |
| BMI, kg/m2 | 27.7 ± 4.8 | 27.0 ± 4.9 | 25.9 ± 4.5 |
| Waist circumference, cm | 94.5 ± 13.4 | 90.9 ± 13.5 | 87.1 ± 12.8 |
| Fasting insulin, pmol/L | 53.9 ± 40.0 | 47.3 ± 31.7 | 41.6 ± 37.5 |
| Fasting glucose, mmol/L | 4.9 ± 0.8 | 4.8 ± 0.6 | 4.8 ± 0.6 |
| 2-h glucose, mmol/L | 5.4 ± 1.8 | 5.3 ± 1.7 | 5.1 ± 1.6 |
| HOMA-IR | 12.3 ± 10.9 | 10.6 ± 8.2 | 9.2 ± 9.5 |
| Systolic blood pressure, mm Hg | 125.1 ± 15.3 | 122.9 ± 15.1 | 120.4 ± 15.2 |
| Diastolic blood pressure, mm Hg | 76.2 ± 10.3 | 74.6 ± 10.0 | 72.9 ± 9.9 |
| Total cholesterol, mmol/L | 5.5 ± 1.0 | 5.4 ± 1.0 | 5.4 ± 1.0 |
| HDL-C, mmol/L | 1.4 ± 0.4 | 1.5 ± 0.4 | 1.6 ± 0.4 |
| LDL-C, mmol/L | 3.5 ± 0.9 | 3.4 ± 0.9 | 3.3 ± 0.9 |
| Cholesterol:HDL-C ratio | 4.1 ± 1.3 | 3.8 ± 1.2 | 3.5 ± 1.1 |
| Triglycerides, mmol/L | 1.3 ± 0.9 | 1.2 ± 0.8 | 1.0 ± 0.7 |
| Energy intake, kcal/d | 2123.2 ± 739.5 | 1925.0 ± 655.8 | 1860.7 ± 603.6 |
Total n = 10,806. Values are means ± SDs or percentages. Adherence to the Mediterranean diet among 10,806 participants recruited at baseline in 2005–2015 in the Fenland Study, using the dietary score derived from the Mediterranean dietary pyramid (see the Methods for details; possible range: 0–15). HDL-C, HDL cholesterol; LDL-C, LDL cholesterol.
For education, compulsory included “school leaving certificate,” “CSE,” and “GCE O level or GCSE”; further included “matriculation,” “GCE A level, AS level, highers,” “technical college exams, city & guilds,” “HND GNVQ,” “completed apprenticeship,” “secretarial college exams,” “teaching diploma, HNC, NVQ,” and “trade certificates”; higher included “university degree.”
For occupation, routine/tech/others included clerical, technical, semiroutine, and routine jobs; managerial/professional included modern professional, senior manager, middle management, and traditional professional jobs.
FIGURE 1Association of the Mediterranean diet with metabolite concentrations: the Fenland Study (n = 10,806, 2005–2015). Percentage difference in metabolite concentrations based on linear regression fitted to data from 10,806 participants (recruited in 2005–2015) for an association of the MDS (per SD) with each of the log-transformed metabolites. Geometric means of metabolites measured in micromoles per liter for the amino acids and biogenic amines, and relative concentrations for the other metabolites. For acylcarnitines, phospholipids, and sphingolipids, numbers of carbons and double bonds of acyl moieties are presented. Correlation represents Spearman's ρ with the MDS. MDS, Mediterranean diet score.
Correlations between the MDS and metabolite scores in the derivation and test sets: the Fenland Study, 2005–2015[1]
| Derivation set | Test set[ | ||||
|---|---|---|---|---|---|
| Strata |
|
| Strata |
|
|
| Metabolite score | |||||
| Random half 1 | 5382 | 0.47 | Random half 2 | 5424 | 0.43 |
| Random half 2 | 5424 | 0.45 | Random half 1 | 5382 | 0.44 |
| Pooled[ | 0.43 | ||||
| Metabolite score from backwards regression | |||||
| Random half 1 | 5382 | 0.45 | Random half 2 | 5424 | 0.42 |
| Random half 2 | 5424 | 0.43 | Random half 1 | 5382 | 0.42 |
| Pooled | 0.42 | ||||
| Metabolite score stratified by age, y | |||||
| ≤48.5 | 5424 | 0.48 | >48.5 | 5382 | 0.42 |
| >48.5 | 5382 | 0.46 | ≤48.5 | 5424 | 0.43 |
| Pooled | 0.42 | ||||
| Metabolite score stratified by sex | |||||
| Men | 5031 | 0.46 | Women | 5775 | 0.40 |
| Women | 5775 | 0.43 | Men | 5031 | 0.43 |
| Pooled | 0.43 | ||||
| Metabolite score stratified by BMI, kg/m2 | |||||
| ≤26.2 | 5470 | 0.47 | >26.2 | 5336 | 0.37 |
| >26.2 | 5336 | 0.40 | ≤26.2 | 5470 | 0.43 |
| Pooled | 0.43 | ||||
| Metabolite score stratified by smoking status | |||||
| Former or current | 4934 | 0.50 | Never | 5874 | 0.42 |
| Never or current | 7236 | 0.46 | Former | 3572 | 0.42 |
| Never or former | 9446 | 0.44 | Current | 1362 | 0.40 |
| Pooled | 0.43 | ||||
| Metabolite score stratified by study site[ | |||||
| Cambridge and Ely | 7794 | 0.46 | Wisbech | 3012 | 0.38 |
| Cambridge and Wisbech | 6817 | 0.48 | Ely | 3989 | 0.40 |
| Ely and Wisbech | 7001 | 0.43 | Cambridge | 3805 | 0.41 |
| Pooled | 0.42 | ||||
Total n = 10,806. MDS, Mediterranean diet score.
Scoring weights were derived from a derivation set, then applied to independent samples (a test set) within the Fenland Study. Then, the mass Spearman's ρ between the metabolite score and the MDS was calculated in the test set.
ρ represents Spearman's ρ of the metabolite scores with the MDS based on the Mediterranean dietary pyramid within the derivation set (subject to an overfitting problem).
Spearman's ρ between the metabolite score and the MDS was calculated by pooling 2 or 3 independent test sets.
Three study sites of the Fenland Study (Cambridge, Ely, and Wisbech in Cambridgeshire, United Kingdom).
Contribution of groups of metabolites to the association between the Mediterranean diet and cardiovascular disease risk factors: the Fenland Study, 2005–2015[1]
| HDL-C, mmol/L | Cholesterol:HDL-C ratio | Triglycerides, % | HOMA-IR, % | |||||
|---|---|---|---|---|---|---|---|---|
| Difference (95% CI)[ | % Attenuation[ | Difference (95% CI)[ | % Attenuation[ | Difference (95% CI)[ | % Attenuation[ | Difference (95% CI)[ | % Attenuation[ | |
| Reference model[ | 0.02 (0.01, 0.02) | −0.05 (−0.07, −0.02) | −1.99 (−2.99, −0.99) | −3.42 (−4.43, −2.40) | ||||
| Adjusted for metabolite subclasses | ||||||||
| + acylcarnitines | 0.02 (0.01, 0.02) | −2.0 | −0.03 (−0.05, −0.00) | 44.7** | −1.01 (−1.99, −0.01) | 48.3** | −2.99 (−4.03, −1.94) | 11.3*** |
| + amino acids/biogenic amines | 0.01 (0.01, 0.02) | 17.0 | −0.05 (−0.07, −0.02) | 1.9 | −1.98 (−3.03, −0.91) | −4.6 | −2.21 (−3.30, −1.11) | 26.4** |
| + lysophosphatidylcholines | 0.02 (0.01, 0.03) | −12.6 | −0.03 (−0.06, −0.01) | 26.0 | −0.63 (−1.58, 0.32) | 67.1* | −3.34 (−4.40, −2.39) | −1.1 |
| + phosphatidylcholine acyl-alkyls | 0.01 (0.01, 0.02) | 8.2 | −0.04 (−0.07, −0.02) | 7.3 | −1.81 (−2.74, −0.87) | 2.3 | −2.52 (−3.64, −1.39) | 27.0*** |
| + phosphatidylcholine diacyls | 0.02 (0.01, 0.02) | −1.7 | −0.06 (−0.08, −0.03) | −4.3 | −1.40 (−2.37, −0.43) | 37.8* | −2.68 (−3.82, −1.53) | 20.8** |
| + sphingolipids | 0.02 (0.01, 0.02) | 7.7 | −0.03 (−0.05, −0.01) | 31.1** | −1.32 (−2.32, −0.29) | 32.0 | −3.02 (−4.04, −1.98) | 8.4** |
| Adjusted for the metabolite score | ||||||||
| + metabolite score[ | 0.01 (0.00, 0.02) | 20.6 | −0.03 (−0.06, −0.01) | 35.6 | −2.01 (−3.37, −0.63) | 8.9 | −1.76 (−3.12, −0.37) | 37.2* |
Total n = 10,806. *P < 0.05, **P < 0.01, ***P < 0.001 for percentage changes. HDL-C, HDL cholesterol.
Values represent unit or percentage differences in cardiovascular disease risk factors [β coefficients or exp(β) and corresponding 95% CIs]; and percentage change in β (see footnote 3). Regression models were fitted with adjustment for age, sex, test site, education level, income, occupation, medication use, family history of diabetes, objectively measured physical activity, smoking, BMI, and waist circumference. Adherence to the Mediterranean diet was not significantly associated with systolic blood pressure, diastolic blood pressure, and 2-h glucose (P > 0.05) and therefore these phenotypes were not considered as potential mediation (see results in Supplemental Table 2).
Percentage changes in β coefficients were calculated as changes in β coefficients from those of the “reference model” upon statistical adjustment for the metabolite score or metabolite subclasses (mediation analysis). As availability of metabolites varied, sample sizes were different across models: reference model, n = 10,806; + acylcarnitines, n = 10,701; + amino acids/biogenic amines, n = 9224; + lysophosphatidylcholines, n = 10,718; + phosphatidylcholine acyl-alkyls, n = 9868; + phosphatidylcholine diacyls, n = 8946; + sphingomyelins, n = 10,690; + metabolite score, n = 7138.
Metabolite score included all 66 metabolites associated with the Mediterranean diet derived in a random half of the total data set and validated in the second half, weighted by their respective regression coefficients.
FIGURE 2Contribution of metabolites to the association between the Mediterranean diet and cardiovascular disease risk factors: the Fenland Study (n = 10,806, 2005–2015). Purple indicates contribution of the particular metabolite to the association of the Mediterranean diet and 1 of the outcomes (the association was attenuated when adjusted for the metabolite). Orange indicates no contribution, where adjustment for the metabolite strengthened the association. All estimates were adjusted for age, sex, test site, education level, income, occupation, medication use, family history of diabetes, objectively measured physical activity, smoking, BMI, and waist circumference. For acylcarnitines, phospholipids, and sphingolipids, numbers of carbons and double bonds of acyl moieties are presented. Chol/HDL-C, cholesterol:HDL cholesterol ratio; DBP, diastolic blood pressure; HDL-C, HDL cholesterol; SBP, systolic blood pressure.